Argenica Therapeutics Ltd · ASX:AGN
Argenica Therapeutics — Investor Presentation (March 2022)
16 slides from Argenica Therapeutics's investor presentation, March 2022
Slide 1: Argenica Therapeutics
ARGENICA THERAPEUTICS MARCH 2022 1 www.argenica.com.au
Slide 2: Disclaimer
This presentation has been prepared by Argenica Therapeutics Limited and its related entities (the “Company”) and is not an offer document. It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You shoul
Slide 3: Granted Patents
ARGENICA THERAPEUTICS GRANTED PATENTS Granted in the EU, Japan Commercialise “best in class” China, and the US novel neuroprotective Neuroprotective peptide therapeutics to reduce brain that could offer protection to cell death following stroke the brain following stroke and FREE OF ENCUMBRANCES and
Slide 4: Shareholders
Total Shares on issue 73,172,250 Other Shareholders ARGENICA THERAPEUTICS Inventors and Research Shares subject to escrow for 24 months 1 22,625,752 SHAREHOLDERS 6 Team Options on issue (escrow for 24 months) 1 & 2 8,300,000 4.7% 5.4% 3.7% 19% 21% 47% Options on issue (not escrowed) 3 300,000 Cash B
Slide 5: Stroke: the unmet need
ONLY 15 MILLION PEOPLE 10 PERCENT WILL LOW RECOVERY HAVE A STROKE RECOVER ALMOST RATE DUE TO BRAIN EACH YEAR1 COMPLETELY 3 CELL DAMAGE ARGENICA THERAPEUTICS Reduction in blood flow leads One in four people will have Long term disability to 1.9 million brain cells a stroke in their lifetime2 Lasting
Slide 6: How It Works
HOW IT WORKS APPLICATIONS Cell death in the brain, or infarction, results from inadequate blood supply to the affected area. ISCHEMIC STROKE EXAMPLE STROKE ARGENICA THERAPEUTICS Initial infarction sets off a cascade ARG-007 has shown significant efficacy in a number of cell death. BRAIN TISSUE DAMAG
Slide 7: Current stroke treatment pathway and cell death
Rapidly increasing level of Long term cell damage impacts neural cell death and damage patient outcomes and recovery ARGENICA THERAPEUTICS IN-FIELD TREATMENT REHAB HOSPITAL TRIAGE PLAN Patient in ambulance and 1-4 weeks acute arrives at emergency Diagnose type of stroke Current therapeutic treatment
Slide 8: Reduction in neural cell death and recovery time
Reduction in Reduction in neural cell death patient recovery and damage time ARGENICA THERAPEUTICS IN-FIELD TREATMENT REHAB HOSPITAL TRIAGE PLAN Patient in ambulance and 1-4 weeks acute arrives at emergency Diagnose type of stroke Current therapeutic treatment hospitalisation1 followed by intensive
Slide 9: ARG-007 preclinical results
REDUCES BRAIN POTENTIAL TO SAFE WITH NO TISSUE DEATH ADMINISTER IN ADVERSE EFFECTS THE FIELD ARGENICA THERAPEUTICS ARG-007 showed a 67% Pre-clinical studies showed ARG-007 No adverse effects were observed in reduction in brain tissue death does not exacerbate bleeding in preliminary PK and toxicolog
Slide 10: Pre-clinical and Phase 1 timeline
ARGENICA THERAPEUTICS Completion of preliminary study activities, including clinical site management setup, preparation of ethics submission and healthy volunteer patient recruitment. ANIMAL STUDY ANIMAL STUDY IN-HUMAN STUDY Determines how is Characterise the safety profile of Ethics submission & ab
Slide 11: Phase 1 trial objectives
1. IMPROVE THE OF HOW EFFECTS THE BODY ARGENICA THERAPEUTICS 2. EVALUATE THE WHEN ADMINISTERED 3. DETERMINE THE 11 4. IDENTIFY ANY POSSIBLE www.argenica.com.au
Slide 12: Phase 1 trial design
ARGENICA THERAPEUTICS 4 cohorts, with each cohort Single site study conducted at Estimated 6 months, with Double-blind, randomised receiving a different dose of the Linear Clinical Research preliminary findings expected study where participants either 8 participants in facility in Western Australia.
Slide 13: Beyond Phase 1: further indications
Data collected from the Phase 1 clinical trial will be critical to progress into Phase 2 trials, where will be administered to stroke patients. While stroke is the current corporate and commercial focus, safety data from the Phase 1 clinical trial can potentially be used ARGENICA THERAPEUTICS to mov
Slide 14: Board and management
Geoff Pocock Dr Liz Dallimore Non-Executive Chairman CEO • 20 years’ experience in commercialisation of emerging • Over 20 years' experience in R&D, technology technologies and capital markets commercialisation and management consulting, including • Non-Executive Director of EMVision Medical Devices
Slide 15: Investment highlights
3# PRE-CLINICAL DATA Positive pre-clinical results provide encouraging dataset leading into in-human trials. ARGENICA THERAPEUTICS 1# CLEAR PATHWAY TO TRIALS 2# 4# 5# Clear clinical pathway and EXCEPTIONAL NEAR TERM robust capital position to UNMET CLINICAL NEED TEAM CATALYSIS execute Phase 1 clinic
Slide 16: Contact
ARGENICA THERAPEUTICS For further information please contact: Dr Liz Dallimore CEO E: info@argenica.com.au 16 www.argenica.com.au
Argenica Therapeutics — Investor Presentation (March 2022) on 6ix